The influence of UGT polymorphisms as biomarkers in solid organ transplantation

Clinica Chimica Acta

Volumn 413, Issue 17-18, 2012, Pages 1318-1325

  Dupuis, Robert ^a   Yuen, Andrea ^a   Innocenti, Federico ^a,b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Mycophenolic acid; Pharmacogenetics; Rejection; Toxicity; Transplantation; UGT

Indexed keywords

ACYL GLUCURONIDE; AZATHIOPRINE; BIOLOGICAL MARKER; CYCLOSPORIN; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; IMMUNOSTIMULATING AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANEMIA; AREA UNDER THE CURVE; BONE MARROW TOXICITY; COLITIS; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME MECHANISM; GASTRITIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; LIVER METABOLISM; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

BIOLOGICAL MARKERS; GLUCURONOSYLTRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; POLYMORPHISM, GENETIC;

EID: 84862757301     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.01.031     Document Type: Review

References (61)

1. Gaston R.S. Current and evolving immunosuppressive regimens in kidney transplantation. Am J Kidney Dis 2006, 47:S3-S21.
2. Halloran P.F. Immunosuppressive drugs for kidney transplantation. NEJM 2004, 351:2715-2729.
3. Glubb D.M., Innocenti F. Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters. Wiley Interdiscip Rev Syst Biol Med 2011, 3:299-313.
4. Ramírez J., Ratain M.J., Innocenti F. Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol 2010, 6:563-585.
5. Desai A.A., Innocenti F., Ratain M.J. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics 2003, 13:517-523.
6. Innocenti F., Liu W., Fackenthal D., et al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics 2008, 18:683-697.
7. Strassburg C.P., Barut A., Obermayer-Straub P., et al. Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. J Hepatol 2001, 34:865-872.
8. Laverdiere I., Caron P., Harvey M., et al. In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4. Drug Metab Dispos 2011, 39:1127-1130.
9. Cianco I. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 2005, 80:S191-S200.
10. Health Resources and Services Administration Organ procurement and transplant network World Wide Web accessed July 18, 2011:. http://optn.transplant.hrsa.gov/ar2009/109a_dh.pdf.
11. Sanford M., Keating G.M. Enteric coated mycophenolate sodium. A review of its use in the prevention of renal transplant rejection. Drugs 2008, 68:2506-2533.
12. Staatz C.E., Tett S.E. Clinical Pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46:13-58.
13. Shipkova M., Armstrong V.M., Oellerich M., Weiland E. Acylglucuronide drug metabolites. Toxicological and analytical implications. Ther Drug Monit 2003, 25:1-16.
14. Knight S.R., Morris P.J. Does evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice. A systemic review. Transplantation 2008, 85:1675-1685.
15. Rosso F.C., Veras de Sandes L.F., Mandia Sampaio F.I., Park S.I., Tedesco Silva H., Medina Pesatvav O. Clinical impact of polymorphisms of transplant proteins and enzymes involved in drug metabolism of immunosuppressive drugs. Transplant Proc 2009, 41:1441-1455.
16. Kuypers D.R., Naesens M., Vermiere S., Vanrenterghem Y. The impact of uridine diphosphate-glucuronyltransferase 1A(UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005, 78:351-361.
17. Kuypers D.R., Dejonge H., Naesens M., et al. Current target ranges of mycophenolic acid exposure and drug related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008, 30:673-683.
18. Barraclough K.A., Staatz C.E., Elizabeth C., Isbel N.M., Johnson D.W. Therapeutic monitoring of mycophenolate in transplantation: is it justified?. Curr Drug Metab 2009, 10:179-187.
19. vanGelder T., Silva H.T., deFijter J.W., Johan W., Budde K., Kuypers D.R. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients; the fixed-dose concentration-controlled trial. Transplantation 2008, 86:1043-1051.
20. LeMeur Y., Buchler M., Thierry A., et al. Individualized mycophenolate dosing based on drug exposure significantly improves outcomes after renal transplantation. Am J Transplant 2007, 7:2496-2503.
21. van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant 2009, 9:1495-1499.
22. deWinter B.C., van Gelder T., Glander P., et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant. Clin Pharmacokinet 2008, 47:827-838.
23. Kuypers D.R., LeMeur Y., Cantarovich M., et al. Consensus report on the therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010, 5:341-358.
24. Picard N., Ratanasavanh D., Premaud A., Le Meur Y., Marquest P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005, 33:139-146.
25. Bernard O., Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 2004, 32:775-778.
26. Bernard O., Tojcic J., Jorunalt J., Perusse L., Guillemette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos 2006, 34:1539-1545.
27. Villenueve L., Girard H., Fortier L.C., Gagne J.F., Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 2003, 307:117-128.
28. Duguay Y., Baar C., Skorpen F., Guillemette C. A novel functional polymorphisms in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004, 75:223-233.
29. Girard H., Court M.H., Bernard O., et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004, 14:501-515.
30. Sanchez Frutuoso A.I., Maestro N., Calvo M., et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms t-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant Proc 2009, 41:2313-2316.
31. van Schaik R.H., van Agteren M., DeFijter J.W., et al. UGT1A9-275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 2009, 86:319-327.
32. Johnson L.A., Oetting W.S., Basu S., Prausa S., Matas A., Jacobson P.A. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur J Clin Pharmacol 2008, 64:1047-1056.
33. Catteneo D., Perico N., Gaspari F., Gotti E., Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002, 62:1060-1067.
34. Djebli N., Picard N., Rerolle J.P., LeMeur Y., Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 2007, 17:321-333.
35. Kobayashi M., Satoh H., Kobayashi M., Tadano K., Takahashi Y., Hirano T. Cyclosporine A but not tacrolimus inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004, 309:1029-1035.
36. Hesselink D.A., Reinier N., VanHest R.A., et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005, 5:978-994.
37. Baldelli S., Merlini S., Perico N., et al. C-440/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 2007, 8:1127-1141.
38. Picard N., Yee S.W., Woliiard J.B., et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 2010, 87:100-108.
39. Gourishankar S., Houde I., Keown P.A., et al. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol 2010, 5:1282-1289.
40. Barraclough K.A., Lee K.J., Staatz C.E. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 2010, 11:369-390.
41. Inoue K., Miura M., Satoh S., et al. Influence of 1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit 2007, 29:299-304.
42. Kagaya H., Inoue K., Miura M., et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007, 63:279-288.
43. Zhang W.X., Chen B., Jin Z., et al. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica 2008, 38:1422-1436.
44. Miura M., Kagay H., Satoh S., et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese transplant recipients. Ther Drug Monit 2008, 30:559-564.
45. Kuypers D.R., Vanrenterghem Y., Squifflet J.P., et al. Twelve month evaluation of clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal transplant recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003, 25:609-622.
46. Shipkova M., Armstrong V.W., Weber L., et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002, 24:390-399.
47. Stracke S., Shipkova M., Mayer J.L., et al. Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early phase post-kidney transplantation. Clin Transplant 2011, 25:1-10.
48. van Agteren M., Armstrong V.W., van Schaik R.H., et al. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. Ther Drug Monit 2008, 30:439-444.
49. Ting L.S., Benoit-Biancamano M.O., Bernard O., Riggs H.W., Guillemette C., Ensom M.H. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. Pharmacotherapy 2010, 30:1097-1108.
50. Collins A.J., Foley R.N., Herzog C., et al. Excerpts from the US renal data system 2009 annual data report. Transplantation. Am J Kidney Dis 2010, 55:S281-S294.
51. Christie J.D., Edwards A.B., Kucheyavaga A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: 27th official adult lung and heart-lung transplantation report. J Heart Lung Transplant 2010, 29:1104-1118.
52. Michelon H., Konig J., Durrbach A., et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 2010, 11:1703-1713.
53. Knoll G.A., MacDonald I., Khan A., van Walraven C. Mycophenolate dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003, 14:2381-2386.
54. Woillard J.B., Rerolle J.P., Picard N., et al. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. Br J Clin Pharmacol 2010, 69:675-683.
55. Yang J.W., Lee P.H., Hutchinson I.V., Pravica V., Shah T., Min D.I. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther Drug Monit 2009, 31:542-548.
56. Betonico G.N., Abbud-Filho M., Goloni-Bertollo E.M., et al. Influence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in kidney transplant patients. Transplant Proc 2008, 40:708-710.
57. Prausa P.E., Fukuda T., Maseck D., et al. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther 2009, 85:495-500.
58. Gieser G., Harigaya H., Colangelo P.M., Burckart G. Biomarkers in solid organ transplant. Clin Pharmacol Ther 2011, 90:217-220.
59. Badde K., Matz M., Durr M., Glander P. Biomarkers of over-immunosuppression. Clin Pharmacol Ther 2011, 90:316-322.
60. Byrne R., Yost S.E., Kaplan B. Mycophenolate mofetil monitoring: is there evidence that it can improve outcomes. Clin Pharmacol Ther 2011, 90:204-206.
61. van Gelder T. Therapeutic drug monitoring for mycophenolic acid is value for little money. Clin Pharmacol Ther 2011, 90:203-204.